Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.13B |
| 2 |
Eaton
ETN
|
+$1.11B |
| 3 |
Analog Devices
ADI
|
+$867M |
| 4 |
Progressive
PGR
|
+$792M |
| 5 |
Datadog
DDOG
|
+$693M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$1.7B |
| 2 |
NVIDIA
NVDA
|
+$1.45B |
| 3 |
Salesforce
CRM
|
+$1.22B |
| 4 |
Advanced Micro Devices
AMD
|
+$1.2B |
| 5 |
lululemon athletica
LULU
|
+$1.11B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 39.74% |
| 2 | Consumer Discretionary | 15.53% |
| 3 | Communication Services | 13.54% |
| 4 | Healthcare | 12.18% |
| 5 | Financials | 8.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
DuPont de Nemours
DD
$18.5B
| $38.7M | 0.02% |
383,434
+38,644
| +11% | +$3.78M |
|
|
EXAS
252
DELISTED
Exact Sciences
EXAS
| $38.7M | 0.02% |
915,434
+281,805
| +44% | +$15.5M |
|
253
Darling Ingredients
DAR
$9.64B
| $38.6M | 0.02% |
1,050,595
-512,144
| -33% | -$21.2M |
|
254
LiveRamp
RAMP
$2.3B
| $38.5M | 0.02% |
1,245,755
-161,343
| -11% | -$5.18M |
|
|
AZEK
255
DELISTED
The AZEK Co
AZEK
| $38.3M | 0.02% |
909,484
-3,005
| -0.3% | -$139K |
|
256
GE HealthCare
GEHC
$30.7B
| $37.9M | 0.02% |
486,961
-207,389
| -30% | -$16.9M |
|
257
CoStar Group
CSGP
$11.7B
| $37.7M | 0.02% |
509,151
+200
| +0% | +$16.9K |
|
258
Varonis Systems
VRNS
$4.59B
| $37.5M | 0.02% |
782,289
-369
| -0% | -$16.3K |
|
|
GLDD
259
DELISTED
Great Lakes Dredge & Dock
GLDD
| $37.4M | 0.02% |
4,254,351
-105,374
| -2% | -$896K |
|
260
Celldex Therapeutics
CLDX
$2.99B
| $37.1M | 0.02% |
1,003,085
+315,005
| +46% | +$11.9M |
|
261
Ryan Specialty Holdings
RYAN
$5.72B
| $37M | 0.02% |
639,697
+202,038
| +46% | +$10.8M |
|
262
Kosmos Energy
KOS
$1.6B
| $36.9M | 0.02% |
6,669,372
+390,619
| +6% | +$2.28M |
|
263
Cameco
CCJ
$37.6B
| $36.8M | 0.02% |
747,461
+42,167
| +6% | +$2.14M |
|
264
Dorman Products
DORM
$3.98B
| $36.5M | 0.02% |
399,237
+115,850
| +41% | +$10.6M |
|
|
HOLX
265
DELISTED
Hologic
HOLX
| $35.8M | 0.02% |
482,344
+4,243
| +0.9% | +$318K |
|
266
Utz Brands
UTZ
$1.25B
| $34.7M | 0.02% |
2,086,678
+755,097
| +57% | +$13.6M |
|
267
Flywire
FLYW
$1.98B
| $34.7M | 0.02% |
2,114,532
+253,581
| +14% | +$4.79M |
|
268
Xylem
XYL
$27.3B
| $34.6M | 0.02% |
255,450
+29,250
| +13% | +$3.98M |
|
269
Lowe's Companies
LOW
$117B
| $34.5M | 0.02% |
156,510
+49,364
| +46% | +$11.3M |
|
270
Oneok
OKE
$57.2B
| $34.2M | 0.02% |
419,113
-97,010
| -19% | -$7.75M |
|
271
Enpro
NPO
$6.63B
| $33.9M | 0.02% |
232,664
-214,159
| -48% | -$32.4M |
|
272
Bristol-Myers Squibb
BMY
$133B
| $33.9M | 0.02% |
815,466
-250,449
| -23% | -$11.2M |
|
273
Littelfuse
LFUS
$11.2B
| $33.4M | 0.02% |
130,837
+99,117
| +312% | +$24.5M |
|
274
Progyny
PGNY
$2.44B
| $33.4M | 0.02% |
1,167,962
-1,428,460
| -55% | -$43M |
|
275
Darden Restaurants
DRI
$23.3B
| $33.4M | 0.02% |
220,650
+13,485
| +7% | +$2.05M |
|
Similar funds
Jennison Associates's Q2 2024 Portfolio in Review
As of Q2 2024, Jennison Associates held 620 positions worth $156B, up 4.3% from $150B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Jennison Associates's Q2 2024 filing shows 48 new, 288 increased, 229 reduced and 48 closed positions. Its largest new stake was Analog Devices: 4,062,204 shares worth $927M. The largest sale was UnitedHealth, an estimated $1.7B.
By sector, the portfolio is most concentrated in Technology at 40% of assets, up from 39% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q2 2024 buy was Analog Devices: 4,062,204 shares worth $927M.
- Jennison Associates added most to Apple in Q2 2024, an estimated $2.13B increase.
- Jennison Associates's biggest Q2 2024 reduction was UnitedHealth, cutting an estimated $1.7B.
- Jennison Associates fully exited Estee Lauder in Q2 2024, selling an estimated $291M.
- Jennison Associates's ten largest holdings make up 48% of its $156B portfolio in Q2 2024.
- Jennison Associates opened 48 new positions and closed 48 in Q2 2024.
- Jennison Associates's portfolio value rose 4.3% quarter-over-quarter to $156B.
Based on Jennison Associates's 13F filing for Q2 2024, filed 5 Aug 2024.